Sotera Health Company: Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
Sotera Health (Nasdaq: SHC) reported Q2 2026 net revenues up 9.2% (8.0% constant currency) to $?, with net income $54 million ($0.19/share) versus $8 million ($0.03) a year earlier. Adjusted EPS was $0.26, and Adjusted EBITDA margin rose to 51.6%. The company raised FY 2026 outlook for net revenues to $1.236-$1.254B and Adjusted EBITDA to $634-$643M.
How this was made
The 30-second read
Why it matters
The company reported Q2 2026 net revenue growth, higher Adjusted EPS, expanded Adjusted EBITDA margin, improved net leverage, and then raised full-year 2026 revenue and Adjusted EBITDA outlook ranges.
Market read
A same-day earnings and guidance update with explicit FY 2026 ranges and balance-sheet actions (term loan repricing) creates a clear catalyst for repricing 2026 expectations.
What to watch
The release flags inability to reconcile certain forward-looking non-GAAP items and cites regulatory and supply-chain uncertainties, which can drive volatility despite the guidance raise.
Background
Sotera Health provides sterilization solutions, lab testing, and advisory services, with results reported by Sterigenics, Nordion, and Nelson Labs segments.
Ticker impact
Sotera Health raised FY 2026 net revenue growth to 5.25% to 6.75% and Adjusted EBITDA growth to 5.75% to 7.25% after strong Q2 results.
Likely positive near-term bias as traders reprice FY 2026 revenue and Adjusted EBITDA expectations; follow-through depends on execution and regulatory/supply-chain risks.
The article discloses a same-day full-year outlook increase with specific ranges, alongside Q2 operating cash flow, net leverage improvement to 3.0x, and repriced term loan savings.
Market effects
Reinforces demand durability for sterilization and lab testing services in regulated healthcare, potentially supporting sentiment for peers exposed to similar end-market spend.
Limited direct regional spillover; primarily US-listed healthcare services sentiment.
Global operations and constant-currency growth highlight resilience to FX, relevant for multinational healthcare services positioning.
Counterpoint
Raised outlook may still be sensitive to regulatory landscape and supply continuity assumptions (ethylene oxide and Cobalt-60), so upside may be capped if those risks re-emerge.
Key entities
- companySotera Health Company
Nasdaq-listed provider of sterilization solutions and lab testing services that reported Q2 2026 results and raised FY 2026 guidance.
- segmentSterigenics
Sotera Health segment with reported constant-currency revenue growth and margin improvement in Q2 2026.
- segmentNordion
Sotera Health segment with reported constant-currency revenue growth and margin improvement in Q2 2026.
- segmentNelson Labs
Sotera Health segment with reported constant-currency revenue growth and sequential margin improvement in Q2 2026.
